Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRING: Safety of Fingolimod in Taiwanese Patients With Relapsing-remitting Multiple Sclerosis
NCT04480853Phase 4Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2020
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of fingolimod in multiple sclerosis (MS), sponsored by Novartis. Started Oct 2020; status: active, not recruiting.
02
Drugs
fingolimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04480853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04480853.